IL205432A0 - Method of identigfying safe nmda receptor antagonists - Google Patents
Method of identigfying safe nmda receptor antagonistsInfo
- Publication number
- IL205432A0 IL205432A0 IL205432A IL20543210A IL205432A0 IL 205432 A0 IL205432 A0 IL 205432A0 IL 205432 A IL205432 A IL 205432A IL 20543210 A IL20543210 A IL 20543210A IL 205432 A0 IL205432 A0 IL 205432A0
- Authority
- IL
- Israel
- Prior art keywords
- identigfying
- receptor antagonists
- nmda receptor
- safe
- safe nmda
- Prior art date
Links
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98592207P | 2007-11-06 | 2007-11-06 | |
| US98592407P | 2007-11-06 | 2007-11-06 | |
| PCT/US2008/082660 WO2009061935A2 (en) | 2007-11-06 | 2008-11-06 | Methods of identifying safe nmda receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL205432A0 true IL205432A0 (en) | 2010-12-30 |
Family
ID=40626437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL205432A IL205432A0 (en) | 2007-11-06 | 2010-04-29 | Method of identigfying safe nmda receptor antagonists |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2212694A4 (es) |
| JP (1) | JP2011503013A (es) |
| KR (1) | KR20100100858A (es) |
| CN (1) | CN101918832A (es) |
| AU (1) | AU2008323877A1 (es) |
| BR (1) | BRPI0820406A2 (es) |
| CA (1) | CA2704475A1 (es) |
| EA (1) | EA201070571A1 (es) |
| IL (1) | IL205432A0 (es) |
| MX (1) | MX2010004971A (es) |
| WO (1) | WO2009061935A2 (es) |
| ZA (1) | ZA201003724B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014159960A (ja) * | 2011-06-08 | 2014-09-04 | Astellas Pharma Inc | 慢性疼痛モデル動物における自発痛行動自動測定法 |
| KR20240068766A (ko) * | 2015-05-22 | 2024-05-17 | 비스타젠 쎄라퓨틱스, 인크. | L-4-클로로키누레닌의 치료적 용도 |
| EP3383429B1 (en) | 2015-11-30 | 2020-10-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Nmdar antagonists for the treatment of tumor angiogenesis |
| CN111960514A (zh) * | 2020-08-28 | 2020-11-20 | 浙江浙能技术研究院有限公司 | 一种用于脱硫废水浓缩的电渗析智能控制系统及方法 |
| CN118019541A (zh) | 2021-09-02 | 2024-05-10 | 埃默里大学 | 在酸性pH下具有增强的效力的N-甲基-D-天冬氨酸受体的GLUN2B-亚基选择性拮抗剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1436258A4 (en) * | 2001-03-08 | 2005-03-23 | Univ Emory | PH VALVE DEPENDENT NMDA RECEPTOR ANTAGONISTS |
| KR20030063765A (ko) * | 2002-01-24 | 2003-07-31 | 엘지전자 주식회사 | 광픽업용 대물렌즈 |
| UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| WO2005061536A1 (en) * | 2003-12-16 | 2005-07-07 | Aventis Pharmaceuticals Inc. | Secreted neural apoptosis inhibiting proteins |
| EP1791569A4 (en) * | 2004-08-23 | 2009-12-16 | Univ Emory | Improved selection of-ph dependent compounds for in vivo therapy |
-
2008
- 2008-11-06 JP JP2010532343A patent/JP2011503013A/ja active Pending
- 2008-11-06 CN CN2008801240927A patent/CN101918832A/zh active Pending
- 2008-11-06 MX MX2010004971A patent/MX2010004971A/es active IP Right Grant
- 2008-11-06 AU AU2008323877A patent/AU2008323877A1/en not_active Abandoned
- 2008-11-06 WO PCT/US2008/082660 patent/WO2009061935A2/en not_active Ceased
- 2008-11-06 BR BRPI0820406-3A patent/BRPI0820406A2/pt not_active IP Right Cessation
- 2008-11-06 EA EA201070571A patent/EA201070571A1/ru unknown
- 2008-11-06 EP EP08847388A patent/EP2212694A4/en not_active Withdrawn
- 2008-11-06 CA CA2704475A patent/CA2704475A1/en not_active Abandoned
- 2008-11-06 KR KR1020107012419A patent/KR20100100858A/ko not_active Withdrawn
-
2010
- 2010-04-29 IL IL205432A patent/IL205432A0/en unknown
- 2010-05-25 ZA ZA2010/03724A patent/ZA201003724B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010004971A (es) | 2010-07-28 |
| EP2212694A2 (en) | 2010-08-04 |
| CN101918832A (zh) | 2010-12-15 |
| AU2008323877A1 (en) | 2009-05-14 |
| EP2212694A4 (en) | 2011-10-12 |
| JP2011503013A (ja) | 2011-01-27 |
| BRPI0820406A2 (pt) | 2015-05-19 |
| ZA201003724B (en) | 2013-10-30 |
| WO2009061935A3 (en) | 2009-08-20 |
| CA2704475A1 (en) | 2009-05-14 |
| KR20100100858A (ko) | 2010-09-15 |
| WO2009061935A2 (en) | 2009-05-14 |
| EA201070571A1 (ru) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2129654E (pt) | Antagonistas do receptor de glucagina | |
| AP2739A (en) | Azaindazole compounds as CCRI receptor antagonists | |
| ZA201001874B (en) | Nmda receptor antagonists for neuroprotection | |
| GB2456192B (en) | Dust-separating apparatus | |
| IL208895A0 (en) | Nmda receptor antagonists for the treatment of neuropsychiatric disorders | |
| PL2927224T3 (pl) | Antagoniści receptora | |
| EP2184278A4 (en) | P2X4 RECEIVER ANTAGONIST | |
| EP2058304A4 (en) | P2X4 RECEPTOR ANTAGONIST | |
| ZA201103156B (en) | Isonicotinamide orexin receptor antagonists | |
| EP2350024A4 (en) | IMPROVED METHOD FOR THE PRODUCTION OF ENDOTHELIN RECEPTOR ANTAGONISTS | |
| ZA201006587B (en) | Methods for treating disorders using nmda nr2b-subtype selective antagonist | |
| PL2799428T3 (pl) | Antagoniści glukagonu | |
| EP2191830A4 (en) | SOLID PREPARATION COMPRISING A NPYY5 RECEPTOR ANTAGONIST | |
| IL217526A0 (en) | Carbocyclic glyt1 receptor antagonists | |
| EP2617717A4 (en) | ANTAGONIST OF P2X4 RECEIVER | |
| ZA201005341B (en) | Methods for inhibiting angiogenesis using egfl8 antagonists | |
| IL205949A0 (en) | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | |
| IL200380A0 (en) | Mineralcorticoid receptor antagonists for the treatment of endometriosis | |
| IL205432A0 (en) | Method of identigfying safe nmda receptor antagonists | |
| IL241743A0 (en) | Non-competitive nicotinic receptor antagonists | |
| ZA200903496B (en) | Spiro-piperidine derivatives as via receptor antagonists | |
| EP2367810A4 (en) | CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS | |
| IL211996A0 (en) | Process for the preparation of substituted phenylalanines | |
| IL207438A0 (en) | 2-aminoquinolines as 5-ht5a receptor antagonists | |
| EP2173695A4 (en) | PROCESS FOR THE PREPARATION OF CIS-4-TERT.-BUTYLCYCLOHEXANOL |